前立腺がん治療の世界市場レポート 2025年

前立腺がん治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で181億6,000万米ドルに成長します。予測期間中の成長は、新興国におけるヘルスケア支出の増加、がん治療への投資の増加、先進的画像診断・診断ツールの普及、低侵襲・非外科的治療の採用拡大などの要因によるものと考えられます。予測期間における主要動向としては、標的がん治療の発展、精密がん医療の統合、技術を駆使した画像診断ツールの開発、放射性リガンドを用いた治療の進歩、前立腺がんに対する免疫療法の継続的な進歩などが挙げられます。

前立腺がんの罹患率の増加は、前立腺がん治療市場の成長を促進すると予想されます。前立腺がんは、前立腺に悪性細胞が形成される疾患で、主に高齢男性が罹患します。前立腺がんの罹患数の増加は、高齢化が主要原因であり、この病気を開発するリスクは年齢とともに大幅に増加するからです。平均寿命が長くなったことも、この疾患を発症するほど長生きする男性が増えたことを意味します。前立腺がん治療は、手術、放射線療法、ホルモン療法、免疫療法などの新しい選択肢といった治療を通じて、がん細胞を標的とし、進行を遅らせ、生活の質を向上させることによって、この病気を管理することを目指しています。例えば、2024年10月、英国の国民保健サービス（NHS）は、2022年に男性のがん診断が16万7,917例から18万877例へと7％増加したと報告しました。この増加の大部分は前立腺がんによるもので、25％以上増加し、5万4,732例に達しました。この前立腺がんの罹患率の増加が、前立腺がん治療市場の拡大を牽引しています。

前立腺がん治療市場の主要企業は、患者のコンプライアンスと治療成果を高めるため、進行性前立腺がん用の1日1回経口薬などの革新的なソリューションを導入しています。これらの経口剤は毎日服用し、がん細胞に対するテストステロンの作用を阻害することで転移性去勢抵抗性前立腺がんを管理します。例えば、2024年1月、インドの製薬会社ザイダス・ライフサイエンシズは、進行前立腺がん患者を対象に、レルゴリックスを含有するインド初の経口1日1回投与錠剤レキシゴを発売しました。注射によるホルモン療法に代わるこの便利で手頃な価格の治療は、テストステロンを速やかに抑制し、がんの増殖を抑え、心血管系の安全性プロファイルを改善することで効果を発揮します。この経口治療により、ヘルスケアプロバイダによる注射治療が不要となり、患者の利便性が向上します。今回の上市は、インドにおける前立腺がん治療における大きな進歩であり、患者と医師に安全で費用対効果の高い新たな治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の前立腺がん治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の前立腺がん治療市場：成長率分析
• 世界の前立腺がん治療市場の実績：規模と成長、2019～2024年
• 世界の前立腺がん治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の前立腺がん治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前立腺がん治療市場：療法別、実績と予測、2019～2024年、2024～2029年、2034年
• ホルモン療法
• 化学療法
• 免疫療法
• 標的療法
• その他の療法
• 世界の前立腺がん治療市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• アンドロゲン受容体阻害剤
• GnRH受容体拮抗薬
• PARP阻害剤
• 免疫チェックポイント阻害剤
• その他
• 世界の前立腺がん治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射
• 世界の前立腺がん治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン販売
• 世界の前立腺がん治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• クリニック
• 病院
• その他
• 世界の前立腺がん治療市場、ホルモン療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 黄体形成ホルモン放出ホルモン（LHRH）作動薬
• Lhrh拮抗薬
• 抗アンドロゲン
• アンドロゲン合成阻害剤
• 世界の前立腺がん治療市場、化学療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ドセタキセル
• カバジタキセル
• ミトキサントロン
• 併用化学療法レジメン
• 世界の前立腺がん治療市場、免疫療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• シプリューセルT
• 免疫チェックポイント阻害剤
• がんワクチン
• サイトカインベース療法
• 世界の前立腺がん治療市場、標的療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• PARP阻害剤
• 放射性リガンド療法
• チロシンキナーゼ阻害剤
• 世界の前立腺がん治療市場、その他の療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 放射線療法
• 骨標的療法
• 凍結療法
• 高強度焦点式超音波

第7章 地域別・国別分析

• 世界の前立腺がん治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の前立腺がん治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺がん治療市場：競合情勢
• 前立腺がん治療市場：企業プロファイル
  • Johnson & Johnson
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Novartis AG
  • AstraZeneca plc

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Astellas Pharma Inc.
• Jiangsu Hengrui Medicine Co. Ltd.
• Telix Pharmaceuticals
• Bayer AG
• Curium Pharma SAS
• Dendreon Pharmaceuticals
• Myovant Sciences GmbH
• Clovis Oncology Inc.
• Ipsen S.A.
• Veru Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Dendreon Pharmaceuticals LLC
• Pfizer Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 前立腺がん治療市場、2029年：新たな機会を提供する国
• 前立腺がん治療市場、2029年：新たな機会を提供するセグメント
• 前立腺がん治療市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Prostate cancer therapeutics encompass a range of medical treatments and interventions designed to manage, control, or eliminate prostate cancer, a type of cancer that forms in the prostate gland of men. These therapies aim to slow disease progression, alleviate symptoms, improve quality of life, and, in some instances, achieve remission.

The primary types of therapies in prostate cancer treatment include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Hormonal therapy is a treatment that modifies hormone levels in the body to address conditions such as cancer or hormonal imbalances. This therapy includes various drug classes such as androgen receptor inhibitors, GnRH receptor antagonists, PARP inhibitors, immune checkpoint inhibitors, and more, which can be administered either orally or through injection. These therapies are distributed via hospital pharmacies, retail pharmacies, and online sales, serving various end users, including clinics, hospitals, and other medical facilities.

The prostate cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer therapeutics market statistics, including prostate cancer therapeutics industry global market size, regional shares, competitors with a prostate cancer therapeutics market share, detailed prostate cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer therapeutics industry. This prostate cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer therapeutics market size has grown strongly in recent years. It will grow from $11.92 billion in 2024 to $13.00 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to several factors, including the rising global incidence of prostate cancer, increased awareness of early cancer screening and diagnostic programs, the growing elderly male population, and a higher demand for personalized and targeted therapies.

The prostate cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as rising healthcare expenditure in emerging economies, increasing investments in oncology drugs, greater availability of advanced imaging and diagnostic tools, and the growing adoption of minimally invasive and non-surgical treatments. Key trends in the forecast period include advancements in targeted cancer therapies, the integration of precision cancer medicine, the development of technology-driven diagnostic imaging tools, progress in radioligand-based treatments, and continued advancements in immunotherapy for prostate cancer.

The increasing incidence of prostate cancer is expected to drive the growth of the prostate cancer therapeutics market. Prostate cancer, a disease where malignant cells form in the prostate gland, primarily affects older men. The rise in prostate cancer incidences is largely attributed to the aging population, as the risk of developing the disease increases significantly with age. Longer life expectancy also means more men are living long enough to develop the condition. Prostate cancer therapeutics aim to manage the disease by targeting cancer cells, slowing its progression, and improving the quality of life through treatments such as surgery, radiation, hormone therapy, and newer options such as immunotherapy. For example, in October 2024, the National Health Service (NHS) in the UK reported that cancer diagnoses among men increased by 7% in 2022, from 167,917 to 180,877 cases. A significant portion of this rise was attributed to prostate cancer, which saw a more than 25% increase, reaching 54,732 cases. This growing incidence of prostate cancer is driving the expansion of the prostate cancer therapeutics market.

Leading companies in the prostate cancer therapeutics market are introducing innovative solutions, such as oral once-a-day pills for advanced prostate cancer, to enhance patient compliance and treatment outcomes. These oral pills are taken daily and manage metastatic castration-resistant prostate cancer by inhibiting the effects of testosterone on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based pharmaceutical company, launched Rexigo, India's first oral once-a-day pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies works by rapidly suppressing testosterone, controlling cancer growth, and offering an improved cardiovascular safety profile. The oral therapy eliminates the need for injectable treatments administered by healthcare providers, offering greater convenience for patients. This launch marks a significant advancement in prostate cancer management in India, providing patients and doctors with a new, safe, cost-effective treatment option.

In June 2024, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. The acquisition strengthens AstraZeneca's portfolio, enabling the development of next-generation radio conjugates that offer more targeted therapies, potentially replacing traditional chemotherapy and radiotherapy treatments. Fusion Pharmaceuticals, a Canada-based clinical-stage oncology company, specializes in therapies for prostate cancer, particularly targeting metastatic castration-resistant prostate cancer (mCRPC).

Major players in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prostate cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer therapeutics market consists of revenues earned by entities by providing services such as medical consultation services, diagnostic services, psychosocial support, clinical trials access, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer therapeutics market also includes sales of hormone therapy medications, chemotherapy drugs, immunotherapy products, and targeted therapy drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy; Other Therapies
• 2) By Drug Class: Androgen Receptor Inhibitors; GnRH Receptor Antagonists; PARP Inhibitors; Immune Checkpoint Inhibitors; Other Drug Classes
• 3) By Route Of Administration: Oral; Injectable
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Sales
• 5) By End User: Clinics; Hospitals; Other End Users
• Subsegments:
• 1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists; LHRH Antagonists; Anti-Androgens; Androgen Synthesis Inhibitors
• 2) By Chemotherapy: Docetaxel; Cabazitaxel; Mitoxantrone; Combination Chemotherapy Regimens
• 3) By Immunotherapy: Sipuleucel-T; Immune Checkpoint Inhibitors; Cancer Vaccines; Cytokine-Based Therapies
• 4) By Targeted Therapy: PARP Inhibitors; Radioligand Therapy; Tyrosine Kinase Inhibitors
• 5) By Other Therapies: Radiotherapy; Bone-Targeted Therapies; Cryotherapy; High-Intensity Focused Ultrasound
• Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Therapeutics Market Characteristics

3. Prostate Cancer Therapeutics Market Trends And Strategies

4. Prostate Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Prostate Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Cancer Therapeutics Market Growth Rate Analysis
• 5.4. Global Prostate Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Cancer Therapeutics Total Addressable Market (TAM)

6. Prostate Cancer Therapeutics Market Segmentation

• 6.1. Global Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Other Therapies
• 6.2. Global Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Androgen Receptor Inhibitors
• GnRH Receptor Antagonists
• PARP Inhibitors
• Immune Checkpoint Inhibitors
• Other Drug Classes
• 6.3. Global Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Prostate Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Sales
• 6.5. Global Prostate Cancer Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Other End Users
• 6.6. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
• Lhrh Antagonists
• Anti-Androgens
• Androgen Synthesis Inhibitors
• 6.7. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Docetaxel
• Cabazitaxel
• Mitoxantrone
• Combination Chemotherapy Regimens
• 6.8. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sipuleucel-T
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• Cytokine-Based Therapies
• 6.9. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parp Inhibitors
• Radioligand Therapy
• Tyrosine Kinase Inhibitors
• 6.10. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiotherapy
• Bone-Targeted Therapies
• Cryotherapy
• High-Intensity Focused Ultrasound

7. Prostate Cancer Therapeutics Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Therapeutics Market

• 8.1. Asia-Pacific Prostate Cancer Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Therapeutics Market

• 9.1. China Prostate Cancer Therapeutics Market Overview
• 9.2. China Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Therapeutics Market

• 10.1. India Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Therapeutics Market

• 11.1. Japan Prostate Cancer Therapeutics Market Overview
• 11.2. Japan Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Therapeutics Market

• 12.1. Australia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Therapeutics Market

• 13.1. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Therapeutics Market

• 14.1. South Korea Prostate Cancer Therapeutics Market Overview
• 14.2. South Korea Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Therapeutics Market

• 15.1. Western Europe Prostate Cancer Therapeutics Market Overview
• 15.2. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Therapeutics Market

• 16.1. UK Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Therapeutics Market

• 17.1. Germany Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Therapeutics Market

• 18.1. France Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Therapeutics Market

• 19.1. Italy Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Therapeutics Market

• 20.1. Spain Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Therapeutics Market

• 21.1. Eastern Europe Prostate Cancer Therapeutics Market Overview
• 21.2. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Therapeutics Market

• 22.1. Russia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Therapeutics Market

• 23.1. North America Prostate Cancer Therapeutics Market Overview
• 23.2. North America Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Therapeutics Market

• 24.1. USA Prostate Cancer Therapeutics Market Overview
• 24.2. USA Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Therapeutics Market

• 25.1. Canada Prostate Cancer Therapeutics Market Overview
• 25.2. Canada Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Therapeutics Market

• 26.1. South America Prostate Cancer Therapeutics Market Overview
• 26.2. South America Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Therapeutics Market

• 27.1. Brazil Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Therapeutics Market

• 28.1. Middle East Prostate Cancer Therapeutics Market Overview
• 28.2. Middle East Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Therapeutics Market

• 29.1. Africa Prostate Cancer Therapeutics Market Overview
• 29.2. Africa Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Therapeutics Market Competitive Landscape
• 30.2. Prostate Cancer Therapeutics Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Astellas Pharma Inc.
• 31.3. Jiangsu Hengrui Medicine Co. Ltd.
• 31.4. Telix Pharmaceuticals
• 31.5. Bayer AG
• 31.6. Curium Pharma SAS
• 31.7. Dendreon Pharmaceuticals
• 31.8. Myovant Sciences GmbH
• 31.9. Clovis Oncology Inc.
• 31.10. Ipsen S.A.
• 31.11. Veru Inc.
• 31.12. Bristol-Myers Squibb Company
• 31.13. F. Hoffmann-La Roche Ltd
• 31.14. Dendreon Pharmaceuticals LLC
• 31.15. Pfizer Inc.

32. Global Prostate Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Therapeutics Market

34. Recent Developments In The Prostate Cancer Therapeutics Market

35. Prostate Cancer Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer